

# BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections

Manik Kohli <sup>1,2</sup>, Nicholas Medland,<sup>3,4</sup> Helen Fifer <sup>5</sup>,  
John Saunders <sup>1,5</sup>

In 2017, BASHH and Public Health England, now the UK Health Security Agency (UKHSA), published a position statement on the use of doxycycline as prophylaxis for STIs.<sup>1</sup> It advised 'extreme caution in the use of doxycycline [as post-exposure prophylaxis (PEP)]...[and] that the use of doxycycline PEP should be restricted to the research setting'. However, increasingly evidence suggests that individuals at higher risk of acquiring bacterial STIs are already using antibiotics to prevent acquisition, accessed through several routes.<sup>2-5</sup> Clinicians are therefore likely to be seeing patients who are self-sourcing antibiotics as STI prophylaxis. For that reason, and to support a person-centred approach to care, the BASHH position statement has been updated. It now includes information about key studies to date and concerns around antimicrobial resistance (AMR) in sexually and non-sexually transmitted infections, as well as providing recommendations for clinicians for how to advise patients about STI prophylaxis. Importantly, it remains the case that doxycycline taken as PEP or pre-exposure prophylaxis (PrEP) for STIs is not endorsed by BASHH or UKHSA. This remains in line with international counterparts.<sup>6</sup> The full position statement is available on the BASHH website: (<https://www.bashh.org/guidelines>).

STI prophylaxis is the use of antibiotics as PEP or PrEP to reduce the risk of acquiring certain bacterial STIs. Only the use of doxycycline to prevent syphilis and chlamydia in men who have

sex with men (MSM) and transgender women has been researched with a single published study powered to show efficacy.<sup>7</sup> This open-label, randomised controlled trial (RCT) explored the efficacy of doxycycline PEP taken as a single 200 mg dose within the first 24 hours, and no later than 72 hours, after condomless sex among 232 MSM and transgender women using HIV-PrEP. A significant decrease was observed in the occurrence of first episode of chlamydia and for first episode of syphilis. No significant difference in the incidence of gonorrhoea was observed. An earlier open-label, pilot RCT of 100 mg doxycycline daily as PrEP involving 30 MSM living with HIV did observe reductions in both syphilis diagnosis, and diagnosis of either chlamydia or gonorrhoea, that were not statistically significant.<sup>8</sup> Several further studies of doxycycline PrEP and PEP are ongoing.<sup>2,9</sup>

Despite the lack of a large evidence base, up to 10% of HIV-PrEP-using MSM report taking antibiotic STI prophylaxis in surveys from the UK, Australia and the Netherlands<sup>2-6</sup> — with comparable reported use among MSM living with HIV.<sup>10</sup> Notably, interest and acceptability for STI prophylaxis among MSM is much higher, ranging from 53% to 84% in surveys.<sup>2,11</sup> STI prophylaxis use has been found to be associated with higher risk behaviours, for example greater numbers of condomless sex partners and chemsex, and is also associated with STI diagnosis in the past 12 months.<sup>3,4</sup> Although the most commonly used antibiotic for STI prophylaxis is doxycycline, emerging evidence suggests that up to 40% of MSM who report having ever used STI prophylaxis used an antibiotic other than doxycycline, such as azithromycin or amoxicillin — where there is no evidence of effectiveness in preventing bacterial STIs.<sup>10</sup>

Concerns exist regarding the emergence of AMR in sexually and non-sexually transmitted infections. Tetracycline resistance has not been demonstrated in *Treponema pallidum* (subsp. *pallidum*), the bacterium

causing syphilis, or meaningfully confirmed in *Chlamydia trachomatis*. However, high rates of tetracycline resistance in *Neisseria gonorrhoeae* already preclude treatment of gonorrhoea with doxycycline, and its use as prophylaxis is not likely to be effective in preventing gonorrhoea infection. Also of major concern is the potential for selection of resistance among potentially pathogenic bacterial flora such as *Staphylococcus aureus* and respiratory tract pathogens. Consideration also needs to be given to the impact on community prevalence of resistance determinants within commensal organisms, with higher prevalence purported among MSM populations.<sup>12</sup>

There remain key gaps in understanding the risk of AMR emergence with prophylactic doxycycline for STIs, as well as some of the facilitators and drivers that lead to individuals' decisions to self-source antibiotics. In addition to addressing the question of efficacy, some current trials examining doxycycline as STI prophylaxis will attempt to address aspects of AMR. In the interim, it is important clinicians ask about antibiotic STI prophylaxis use and discuss the limited benefits and potential risks. This position statement provides an update on the current available evidence and practical guidance for clinicians providing care to individuals reporting antibiotic STI prophylaxis use.

**Handling editor** Anna Maria Geretti

**Twitter** John Saunders @saunders\_j

**Contributors** MK, NM, HF and JMS coauthored the updated position statement. MK wrote the first draft of the manuscript, and all other authors provided comments and edits.

**Funding** MK, a National Institute for Health Research (NIHR) Academic Clinical Fellow (ACF-2020-18-014), is funded by Health Education England (HEE)/NIHR.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; internally peer reviewed.



## OPEN ACCESS

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Institute for Global Health, University College London, London, UK

<sup>2</sup>Department of Sexual Health and HIV, Central and North West London NHS Foundation Trust, London, UK

<sup>3</sup>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

<sup>4</sup>Melbourne Sexual Health Centre, Monash University Central Clinical School, Melbourne, Victoria, Australia

<sup>5</sup>Blood Safety, Hepatitis, STIs and HIV Division, UK Health Security Agency, London, UK

**Correspondence to** Dr Manik Kohli, Institute for Global Health, University College London, London, WC1E 6BT, UK; [m.kohli@ucl.ac.uk](mailto:m.kohli@ucl.ac.uk)



**To cite** Kohli M, Medland N, Fifer H, *et al.*  
*Sex Transm Infect* 2022;**98**:235–236.

*Sex Transm Infect* 2022;**98**:235–236.  
doi:10.1136/sextrans-2022-055425

#### ORCID iDs

Manik Kohli <http://orcid.org/0000-0001-7247-1678>

Helen Fifer <http://orcid.org/0000-0001-7756-403X>

John Saunders <http://orcid.org/0000-0001-9658-7798>

#### REFERENCES

- Public Health England, British Association for Sexual Health and HIV. Position statement on doxycycline as post-exposure prophylaxis for sexually transmitted, 2017. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/656803/Doxy\\_PEP\\_statement\\_v5\\_PHE\\_BASHH.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/656803/Doxy_PEP_statement_v5_PHE_BASHH.pdf)
- Grant JS, Stafylis C, Celum C, *et al.* Doxycycline prophylaxis for bacterial sexually transmitted infections. *Clin Infect Dis* 2020;70:1247–53.
- O'Halloran C, Croxford S, Mohammed H, *et al.* Factors associated with reporting antibiotic use as STI prophylaxis among HIV PreP users: findings from a cross-sectional online community survey, May–July 2019, UK. *Sex Transm Infect* 2021;97:429–33.
- Chow EPF, Fairley CK. Use of doxycycline prophylaxis among gay and bisexual men in Melbourne. *Lancet HIV* 2019;6:e568–9.
- Evers YJ, van Liere GAFS, Dukers-Muijers NHTM, *et al.* Use of doxycycline and other antibiotics to prevent STIs among men who have sex with men visiting sexual health clinics in the Netherlands. *Sex Transm Infect* 2020;96:550–1.
- Workowski KA, Bachmann LH, Chan PA, *et al.* Sexually transmitted infections treatment guidelines, 2021. *MMWR Recomm Rep* 2021;70:1–187.
- Molina J-M, Charreau I, Chidiac C, *et al.* Post-Exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. *Lancet Infect Dis* 2018;18:308–17.
- Bolan RK, Beymer MR, Weiss RE, *et al.* Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. *Sex Transm Dis* 2015;42:98–103.
- ClinicalTrials.gov [Online]. National Library of Medicine (US). Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP (dPEP-KE). Identifier: NCT04050540 (Feb 2020 –). Available: <https://clinicaltrials.gov/ct2/show/NCT04050540>
- Kohli M, Reid D, Pulford CV, *et al.* Choice of antibiotics for prophylaxis of bacterial STIs among individuals currently self-sourcing. *Sex Transm Infect* 2022;98:158.
- Park JJ, Stafylis C, Pearce DD, *et al.* Interest, concerns, and attitudes among men who have sex with men and health care providers toward prophylactic use of doxycycline against Chlamydia trachomatis infections and syphilis. *Sex Transm Dis* 2021;48:615–9.
- Kenyon CR, Schwartz IS. Effects of sexual network connectivity and antimicrobial drug use on antimicrobial resistance in Neisseria gonorrhoeae. *Emerg Infect Dis* 2018;24:1195–203.